JPRN-UMIN000039177已完成未知
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement and its Impact on Skin Parameters in Healthy Female Subjects - A Study Evaluating the Nutritional Supplement on Skin Parameters in Healthy Female Subjects
TTC Co., Ltd0 个研究点目标入组 66 人开始时间: 2020年1月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 35years-old 至 60years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Subjects in menopause. Those on current use or use within 1 month of research enrollment of hormonal therapies. Those on current regular use or regular use within 1 month of research enrollment of steroids. Those in chronic or relapsing inflammatory and/or allergic skin conditions. Pregnant lactating or breastfeeding women. Subjects who have a history of skin cancer or currently have skin cancer. Those currently with active herpes infections or currently on treatment for herpes infections. Those with a history of facial keloids. Those with current diagnosis of adult acne or currently on treatment for adult acne. Those with recent cardiovascular conditions. Those on potent blood thinners. Those with a current diagnosis of diabetes mellitus. Those who have received facial irradiation within the last 1 year or are planning on undergoing facial irradiation during the research. Those with chronic liver disease. Those with chronic kidney disease. Those who currently take supplements containing carotenoids. Those with occupations or lifestyle that require(s) significant daily exposure to the sun. Subjects who have had previous facial irradiation. Those who plan to undergo invasive facial procedures. Those who are HIV positive. Those who are immunosuppressed. Those with a recent diagnosis of a psychiatric condition. Those with chronic connective tissue disorder affecting the skin. Those with autoimmune skin diseases. Those who have been prescribed retinoids treatment. Those who have smoking habits. Those who take excessive amounts of alcoholic drinks. Those who use illicit or illegal drugs. Those who are regular users of cannabis substances or substances derived from cannabis. Those who are planning a trip to the mountains or to a higher UV index region. Those who are experiencing perimenopausal or menopausal symptoms. Those who have had a hysterectomy and/or both of their ovaries removed.
研究者
相似试验
已完成
不适用
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of BMS-207940, a Selective Endothelina Receptor, Antangonist, in Subjects with Intermittent Claudicatio-I739 Peripheral vascular disease, unspecifiedPeripheral vascular disease, unspecifiedI739PER-033-00BRISTOL MYERS SQUIBB PERU S.A.,
进行中（未招募）
1 期
This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEBiliary AtresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850EUCTR2019-003807-37-PLAlbireo AB245
进行中（未招募）
1 期
This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEBiliary AtresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850EUCTR2019-003807-37-HUAlbireo AB200
已完成
不适用
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertensio-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-025-08TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
进行中（未招募）
1 期
This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPEBiliary AtresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-003807-37-DEAlbireo AB245